versus oral tibolone on health-related quality of life (HRQOL) after surgical menopause.
METHODS: In a randomized single-blind trial, Indian women received either oral tibolone
tablets (2.5 mg) or transdermal estradiol gel (0.06%) daily. Each woman scored herself on
the Menopause Rating Scale (MRS) II at the beginning of the study and after 6months.
Independent t tests were used to determine the significance of changes in HRQOL …